c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EDT
UTC-4 New York
Blue Chip
Log in
Sign up
NVS
Novartis AG
stock
NYSE
ADR
Market Open
Oct 5, 2026 11:10:40 AM EDT
139.79
USD
-0.858%
(-1.21)
358,118
139.72
Bid
139.76
Ask
0.04
Spread
Pre-market
Oct 5, 2026 9:28:30 AM EDT
140.93
USD
-0.050%
(-0.07)
After-hours
Overview
Options
Historical
Exchanges
Shorts
News
News
NVS News
1
/
3
Oct 5, 2026
Day breaks
Oct 5, 2026
08:45 AM EDT
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
·
PR Newswire
Oct 4, 2026
09:05 AM EDT
Notable healthcare headlines for the week: Pfizer, Sanofi, and Novartis in focus
·
Seeking Alpha
Oct 2, 2026
01:04 PM EDT
Novartis Signs Deal With Abogen For MRNA Therapies
·
RTTNews
07:32 AM EDT
Medicare drug pricing model to affect only four firms after Trump’s MFN policy
·
Seeking Alpha
03:09 AM EDT
Novartis inks up to $7.8B deal with Abogen for RNA-encoded therapeutics
·
Seeking Alpha
02:47 AM EDT
Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion
·
Bloomberg
Sep 30, 2026
09:28 AM EDT
Merck succeeds in mid-stage trial for skin disease drug
·
Seeking Alpha
Sep 25, 2026
03:00 PM EDT
Catalyst Watch: Jobs report, Trump AI talks, and ticking fee time for Paramount
·
Seeking Alpha
Sep 24, 2026
03:36 PM EDT
FDA commissioner nominee Overton rebuffs questions about Trump medical claims
·
Seeking Alpha
Sep 22, 2026
10:39 AM EDT
Lantheus gains approval of Bravnesta, generic competitor to Lutathera
·
Seeking Alpha
Sep 21, 2026
09:50 PM EDT
Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial
·
Insider Monkey
11:20 AM EDT
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset
·
Seeking Alpha
Sep 18, 2026
07:08 AM EDT
Trump administration is said to weigh allowing most pharma licensing deals with China
·
Seeking Alpha
Sep 17, 2026
11:20 PM EDT
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
·
The Motley Fool
11:00 PM EDT
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
·
The Motley Fool
08:07 PM EDT
Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years
·
Insider Monkey
02:21 PM EDT
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
·
Seeking Alpha
11:21 AM EDT
Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
·
Insider Monkey
Sep 16, 2026
02:20 PM EDT
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022
·
The Motley Fool
02:00 PM EDT
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022
·
The Motley Fool